In Brief: Chiron/Genelabs
This article was originally published in The Gray Sheet
Chiron/Genelabs: Firms finalize agreement under which Chiron and its partner, Johnson & Johnson subsidiary Ortho, gain rights to manufacture and market products based on Genelabs Technologies' hepatitis G virus in exchange for an investment worth up to $24 mil. A proposed agreement was announced in March ("The Gray Sheet" March 13, p. 16)...
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.